Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Fernando Santini
The Activity, Safety, and Evolving Role of Brigatinib in Patients With ALK-rearranged Non-Small Cell Lung Cancers
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.15-10 Determinants of Health Utility Scores (HUS) in Patients With ALK Rearranged Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
Journal of the Advanced Practitioner in Oncology
Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors
Translational Lung Cancer Research
Oncology
P2.01-84 Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
